Paul Lockman, PhD, BSN

Research Interests

Grants and Research

Research Interests
Chemotherapy distribution into brain tumors and metastases
Nanoparticle drug delivery to brain
Effects of nicotine and or smoking on drug distribution
 
Recent and Current Funding
biOasis; Drug Company Contract  “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer; Survival Project”
National Cancer Institute, National Institutes of Health, Bethesda, MD. 1R01CA166067-01A1 “Prevention and Treatment of Brain Micro-metastases of Breast Cancer”
NEKTAR Therapeutics; Drug company contract “Pharmacokinetics and efficacy of NEKTAR-102 in brain metastases of breast cancer”
biOasis; drug company contract “Brain Uptake and In Vivo Activity of a p97-anti HER2 mAbs Conjugate (BTA-p97) in Brain Metastases of Breast Cancer”
Department of Defense, Breast Cancer Research Program. #BC096887. Cationic Chemotherapeutics to Penetrate Both the Blood-Brain Barrier and Brain Metastasis of Breast Cancer Cells via the Choline Transporter.
Department of Defense, Breast Cancer Research Program. # BC050006. Blood-Tumor Barrier Characterization and Nanoparticle Drug Delivery in Brain Metastasis of Breast Cancer.
Microtransponder; Medical Device Grant “Feasibility of microstimulation for targeted BBB disruption.” 
Minority Health Research and Education Grant program. State of Texas Board of Higher Education; Minority Health Research and Education Grant. Innovations in Competency Education: Strengthening the Pipeline.
National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD. U19 MH069059-01. Development of Novel Treatments for Nicotine Addiction.”

Publications

[2018]

• Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE, Pinti MV, Nolan RL, Lockman PR.  Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res. Accepted 27 Mar 2018. 
• Mohammad AS, Griffith JI, Adkins CE, Shah N, Sechrest E, Dolan EL, Terrell-Hall TB, Hendriks BS, Lee H, Lockman PR (2018). Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer. Pharm Res. 2018 Jan 9;35 (2):31.

• Terrell-Hall TB, Nounou MI, El-Amrawy F, Griffith JIG, Lockman PR (2017). Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer. Oncotarget, 8(48):83734-83744. PMCID: PMC5663550
• Logsdon AF, Lucke-Wold BP, Turner RC, Li X, Adkins CE, Mohammad AS, Huber JD, Rosen CL, Lockman PR (2017). A mouse model of focal vascular injury induces astrocyte reactivity, tau oligomers, and aberrant behavior. Arch Neurosci, 4(2). pii: e44254. PMCID: PMC5529099
• Bohn KA, Adkins CE, Nounou MI, Lockman PR (2017). Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden. Front Pharmacol, 8:193. PMCID: PMC5387068
• Terrell-Hall TB, Ammer AG, Griffith JI, Lockman PR (2017). Permeability across novel microfluidic blood-tumor barrier model. Fluids Barriers CNS, 14(1):3. PMCID: PMC5260004
• Venishetty VK, Geldenhuys WJ, Terrell-Hall TB, Griffith JIG, Sondag GR, Safadi FF, Lockman PR (2017). Identification of novel agents for the treatment of brain metastases of breast cancer. Curr Cancer Drug Targets, 17(5):479-485. PMCID: PMC5438904
• Mittapalli RK, Adkins CE, Bohn KA, Mohammad AS, Lockman JA, Lockman PR (2017). Quantitative fluorescence microscopy measures vascular pore size in primary and metastatic brain tumors. Cancer Res, 77(2):238-246. PMCID: PMC5267930

[2016]

• Nounou MI, Adkins CE, Rubinchik E, Terrell-Hall TB, Afroz M, Vitalis T, Gabathuler R, Tian MM, Lockman PR (2016). Anti-cancer antibody tastuzumab-melanotransferrin conjugate (BT2111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: an in-vivo study. Pharm Res, 33(12):2930-2942. PMCID: PMC5267937
• Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E, Palmieri D, Liewehr DJ, Steinberg SM, Kloc W, Izycka-Swieszewska E, Duchnowska R, Nayyar N, Brastianos PK, Steeg PS, Gril B (2016). Alterations in pericyte subpopulations are associated with elevated blood-tumor barrier permeability in experimental brain metastasis of breast cancer. Clin Cancer Res, 22(21):5287-5299. PMCID: PMC5093086
• Bohn KA, Adkins CE, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Shah N, Dolan EL, Nounou MI, Lockman PR (2016). Semi-automated rapid quantification of brain vessel density utilizing fluorescent microscopy. J Neurosci Methods, 270:124-131. PMCID: PMC4981522
• Adkins CE, Mohammad AS, Terrell-Hall TB, Dolan EL, Shah N, Sechrest E, Griffith J, Lockman PR (2016). Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. Clin Exp Metastasis, 33(4):373-83. PMCID: PMC4804888

[2015]

• Adkins CE, Nounou MI, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Jagannathan R, Lockman PR. A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier.Cancer Prev Res (Phila) 2015 Jan; 8(1):68-76. PMID:PMC4311570.
• Adkins CE, Nounou MI, Hye T, Mohammad AS, Terrell-Hall TB, Mohan NK, Eldon MA, Hoch U, Lockman PR. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. BMC Cancer 2015 Oct; 15:685. PMCID: PMC4604629.
• Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR. Molecular determinants of blood-brain barrier permeation. Ther Deliv 2015; 6(8):961-71. PMCID: PMC4675962 [Available on 2016-08-25].
• Puhalla S, Elmquist W, Freyer D, Kleinberg L, Adkins C, Lockman P, McGregor J, Muldoon L, Nesbit G, Peereboom D, Smith Q, Walker S, Neuwelt E. Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol 2015 May; 17(5):639-51. PMCID: PMC4482864.
• Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP,Lockman P, Bai S. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res 2015 Jun; 32(6):2003-14. PMCID: PMC4520542.
• Adkins CE, Nounou MI, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Jagannathan R, Lockman PR. A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrier.Cancer Prev Res (Phila) 2015 Jan; 8(1): 68-76. PMCID: PMC4311570
• Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. Neuro Oncol 2015 Feb; 17(2): 289-95. PMCID: PMC4288517

[2014]

• Cain J, Conway JM, DiVall MV, Erstad BL, Lockman PR, Ressler JC, Schwartz AH, Stolte S, Nemire RE. Report of the 2013-2014 Academic Affairs Committee. Am J Pharm Educ 2014 Dec; 78(10):S23. PMCID: PMC4315223
• Cain J, Campbell T, Congdon HB, Hancock K, Kaun M, Lockman PR, Evans RL. Complex issues affecting student pharmacist debt. Am J Pharm Educ 2014 Sep; 78(7):131. PMCID: PMC4174373
• El-Habashy SE, Nazief AM, Adkins CE, Wen MM, El-Kamel AH, Hamdan AM, Hanafy AS, Terrell TO, Mohammad AS, Lockman PR, Nounou MI. Novel treatment strategies for brain tumors and metastases. Pharm Pat Anal 2014 May; 3(3):279-96. PMCID: PMC4465202